

Gd-IgA1

Widely Used ELISA for
Clinical Research

(KM55)

- ✓ Gold Standard
- ✓ Global Supply
- ✓ Blood & Urine

ELISA & Antibody

Gd-IgA1 ELISA

| | |
|--------------|----------------------|
| Code: | 27600 |
| Sample: | Serum, Plasma, Urine |
| Assay Range: | 1.56 ~ 100 ng/mL |
| Sensitivity: | 0.488 ng/mL |
| Assay Time: | 2.5 hours |


Lot-to-Lot Stability

| Lot | 2K-026 | 2D-128 | 2J-111 | 2K-230 | 2D-313 | | | |
|-------------------|---------------------------|--------|--------|--------|--------|---------|-------|-----|
| 【Control Samples】 | Measurement Value (pg/ml) | | | | | Average | STDEV | CV% |
| High :51.64pg/ml | 56.74 | 48.79 | 54.02 | 55.50 | 51.15 | 52.18 | 2.80 | 5.4 |
| | 49.61 | 52.76 | 51.63 | 47.98 | 51.68 | | | |
| | 56.52 | 48.22 | 52.28 | 53.75 | 52.03 | | | |
| Low :16.73pg/ml | 18.81 | 17.29 | 18.49 | 18.38 | 18.71 | 18.15 | 0.74 | 4.1 |
| | 17.24 | 18.37 | 19.11 | 17.32 | 19.07 | | | |
| | 18.63 | 16.74 | 18.37 | 17.51 | 18.20 | | | |


KM55

KM55 Monoclonal Antibody

| | |
|--------------|-------------|
| Code: | 10777 |
| Application: | IHC |
| Species: | Human |
| Size: | 10µg, 100µg |



Anti-IgA



This product is not intended for diagnostic or medical purposes.

This product is not intended for diagnostic or medical purposes.

| PMID | Cite |
|----------|--|
| 35570983 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. M Mathur et al. <i>Kidney Int Rep.</i> 2022 Feb 8;7(5):993-1003.. |
| 37114051 | Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy. Y Nihei et al. <i>Front Immunol.</i> 2023 Apr 11;14:1165394. |
| 36862654 | cnm-positive <i>Streptococcus mutans</i> is associated with galactose-deficient IgA in patients with IgA nephropathy. Misaki T, et al. <i>PLoS One.</i> 2023 Mar 2;18(3):e0282367. |
| 35683557 | Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy. Y Fukao et al. <i>J Clin Med.</i> 2022 Jun 2;11(11):3173. . |
| 34570260 | IgA glycosylation and immune complex formation in IgAN. Suzuki, H et al. <i>Semin Immunopathol.</i> 2021 Oct;43(5):669-678. |
| 33818625 | IgA vasculitis with nephritis: update of pathogenesis with clinical implications. M.C. Hastings et al. <i>Pediatr Nephrol.</i> 2022 Apr;37(4):719-733. |
| 37286948 | Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression. S Eliasdottir et al. <i>BMC Nephrol.</i> 2023 Jun 7;24(1):160. |
| 35887995 | Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy. Y-T Juan et al. <i>J Clin Med.</i> 2022 Jul 21;11(14):4231. |
| 34764788 | Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study. M Mizerska-Wasiak et al. <i>Cent Eur J Immunol.</i> 2021;46(2):199-209. |
| 33741175 | Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. L Martín-Penagos et al. <i>Nefrologia (Engl Ed).</i> 2021 May-Jun;41(3):311-320. |
| 34177889 | Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Y-L Chiu et al. <i>Front Immunol.</i> 2021 Jun 10;12:638309. |